Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Administration of the Dual E-Selectin/CXCR4 Antagonist, GMI-1359, Results in a Unique Profile of Tumor Mobilization from the Bone Marrow and Facilitation of Chemotherapy in a Murine Model of FLT3 ITD AML

William E. Fogler, PhD, Henry Flanner, MS, Curt Wolfgang, PhD, Jeffrey Allen Smith, Helen M. Thackray, MD, John L Magnani, PhD

Blood (2016) 128 (22): 2826.

https://doi.org/10.1182/blood.V128.22.2826.2826

Published: 2016

Journal Articles

E-Selectin Antagonist GMI-1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers

Dana E. Angelini, MD, Sumana Devata, MD, Angela E. Hawley, Susan A. Blackburn, RN, MBA, Satwinder Grewal, Martina V Hemmer, MA, Henry Flanner, MS, William Kramer, PhD, William E Parker, Yu-Ling Li, MS, MD, Daniel Durant Myers, DVM, MPH, James B. Froehlich, MD MPH, John L Magnani, PhD, Helen M. Thackray, MD, Thomas W. Wakefield, MD, Suman L. Sood, MD MSCE

Blood (2016) 128 (22): 3826.

https://doi.org/10.1182/blood.V128.22.3826.3826

Published: 2016

Journal Articles

First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile

Sumana Devata, MD, Suman L. Sood, MD, Martina V Hemmer, MA, Henry Flanner, MS, William Kramer, PhD, Christine Nietubicz, Angela Hawley, Dana E Angelini, MD, Daniel Durant Myers, DVM, MPH, Susan Blackburn, James Froehlich, MD, Thomas W. Wakefield, MD, John L. Magnani, PhD, Helen M. Thackray, MD

Blood (2015) 126 (23): 1004.

https://doi.org/10.1182/blood.V126.23.1004.1004

Published: 2015

Journal Articles

Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis

Ted Wun, MD, Marilyn J. Telen, MD, Lakshmanan Krishnamurti, MD, Timothy L. McCavit, MD, Laura M DeCastro, MD, Henry Flanner, ME, Frans A. Kuypers, PhD, Sandra K. Larkin, MS, Seungshin Rhee, MS, John L. Magnani, PhD, Helen M. Thackray, MD

Blood (2014) 124 (21): 2704.

https://doi.org/10.1182/blood.V124.21.2704.2704

Published: 2014

Journal Articles

GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease

Lori Styles, MD, Ted Wun, MD, FACP, FRCPA, Laura M. De Castro, MD, Marilyn J. Telen, MD, William Kramer, PhD, Henry Flanner, John L Magnani, PhD, Helen Thackray, MD

Blood (2010) 116 (21): 1632.

https://doi.org/10.1182/blood.V116.21.1632.1632

Published: 2010

NARROW

Administration of the Dual E-Selectin/CXCR4 Antagonist, GMI-1359, Results in a Unique Profile of Tumor Mobilization from the Bone Marrow and Facilitation of Chemotherapy in a Murine Model of FLT3 ITD AML

E-Selectin Antagonist GMI-1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers

First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile

Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis

GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Administration of the Dual E-Selectin/CXCR4 Antagonist, GMI-1359, Results in a Unique Profile of Tumor Mobilization from the Bone Marrow and Facilitation of Chemotherapy in a Murine Model of FLT3 ITD AML

E-Selectin Antagonist GMI-1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers

First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile

Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis

GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only